Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.
The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis.
Jordan
M Kelli
MK
Pharmacy Department, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Burstein
Aaron H
AH
Rock-Kress
Diane
D
Alfaro
Raul M
RM
Pau
Alice K
AK
Kovacs
Joseph A
JA
Piscitelli
Stephen C
SC
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D018592:Cross-Over Studies; D015658:HIV Infections / Q000150:complications / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D008954:Models, Biological; D013411:Sulfadiazine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D014123:Toxoplasmosis / Q000188:drug therapy / Q000209:etiology
D000890:Anti-Infective Agents; D013411:Sulfadiazine